WallStSmart

Dell Technologies Inc (DELL)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Dell Technologies Inc generates 351% more annual revenue ($134.00B vs $29.74B). GILD leads profitability with a 31.0% profit margin vs 6.3%. DELL appears more attractively valued with a PEG of 0.67. DELL earns a higher WallStSmart Score of 74/100 (B).

DELL

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 6.5Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.39

GILD

Strong Buy

68

out of 100

Grade: B-

Growth: 6.0Profit: 9.5Value: 7.3Quality: 6.5
Piotroski: 7/9Altman Z: 1.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DELL.

GILDUndervalued (+42.5%)

Margin of Safety

+42.5%

Fair Value

$221.22

Current Price

$129.16

$92.06 discount

UndervaluedFair: $221.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DELL6 strengths · Avg: 9.7/10
Market CapQuality
$270.14B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
44.3%10/10

Every $100 of equity generates 44 in profit

Revenue GrowthGrowth
87.5%10/10

Revenue surging 87.5% year-over-year

EPS GrowthGrowth
282.5%10/10

Earnings expanding 282.5% YoY

Debt/EquityHealth
-22.1910/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.678/10

Growing faster than its price suggests

GILD6 strengths · Avg: 9.5/10
Return on EquityProfitability
39.2%10/10

Every $100 of equity generates 39 in profit

Profit MarginProfitability
31.0%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
39.3%10/10

Strong operational efficiency at 39.3%

EPS GrowthGrowth
54.8%10/10

Earnings expanding 54.8% YoY

Market CapQuality
$154.33B9/10

Large-cap with strong market position

P/E RatioValuation
16.9x8/10

Attractively priced relative to earnings

Areas to Watch

DELL3 concerns · Avg: 3.0/10
P/E RatioValuation
33.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

Altman Z-ScoreHealth
1.392/10

Distress zone — elevated risk

GILD3 concerns · Avg: 4.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DELL

The strongest argument for DELL centers on Market Cap, Return on Equity, Revenue Growth. Revenue growth of 87.5% demonstrates continued momentum. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bull Case : GILD

The strongest argument for GILD centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.0% and operating margin at 39.3%.

Bear Case : DELL

The primary concerns for DELL are P/E Ratio, Profit Margin, Altman Z-Score.

Bear Case : GILD

The primary concerns for GILD are PEG Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

DELL profiles as a hypergrowth stock while GILD is a value play — different risk/reward profiles.

DELL carries more volatility with a beta of 1.38 — expect wider price swings.

DELL is growing revenue faster at 87.5% — sustainability is the question.

DELL generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

DELL scores higher overall (74/100 vs 68/100) and 87.5% revenue growth. GILD offers better value entry with a 42.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dell Technologies Inc

TECHNOLOGY · COMPUTER HARDWARE · USA

Dell Technologies Inc. designs, develops, manufactures, markets, sells and supports information technology solutions, products and services worldwide. The company is headquartered in Round Rock, Texas.

Visit Website →

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?